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in obese adipose tissue and atherosclerosis
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Abstract 
Background: The metabolic syndrome is becoming increasingly prevalent in the general population that is at 
simultaneous risk for both type 2 diabetes and cardiovascular disease. The critical pathogenic mechanisms underlying 
these diseases are obesity‑driven insulin resistance and atherosclerosis, respectively. To obtain a better understanding 
of molecular mechanisms involved in pathogenesis of the metabolic syndrome as a basis for future treatment strate‑
gies, studies considering both inherent risks, namely metabolic and cardiovascular, are needed. Hence, the aim of this 
study was to identify pathways commonly dysregulated in obese adipose tissue and atherosclerotic plaques.
Methods: We carried out a gene set enrichment analysis utilizing data from two microarray experiments with obese 
white adipose tissue and atherosclerotic aortae as well as respective controls using a combined insulin resistance‑
atherosclerosis mouse model.
Results: We identified 22 dysregulated pathways common to both tissues with p values below 0.05, and selected 
inflammatory response and oxidative phosphorylation pathways from the Hallmark gene set to conduct a deeper 
evaluation at the single gene level. This analysis provided evidence of a vast overlap in gene expression alterations in 
obese adipose tissue and atherosclerosis with Il7r, C3ar1, Tlr1, Rgs1 and Semad4d being the highest ranked genes for 
the inflammatory response pathway and Maob, Bckdha, Aldh6a1, Echs1 and Cox8a for the oxidative phosphorylation 
pathway.
Conclusions: In conclusion, this study provides extensive evidence for common pathogenic pathways underlying 
obesity‑driven insulin resistance and atherogenesis which could provide a basis for the development of novel strate‑
gies to simultaneously prevent type 2 diabetes and cardiovascular disease in patients with metabolic syndrome.
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Background
The metabolic syndrome is a worldwide public health 
challenge with a prevalence above 20 % within adults in 
Western societies [1]. This disorder is based on several 
factors including visceral obesity, hypertension, dyslipi-
demia and hyperglycemia conferring a fivefold increased 
risk for type 2 diabetes and twofold for cardiovascular 
disease compared to the non-affected population [2, 3]. 
A chronic low-grade inflammation in response to obe-
sity originating from the white adipose tissue has been 
identified as the link between obesity, insulin resistance, 
type 2 diabetes and cardiovascular disease [4–7]. Due to 
the simultaneous occurrence of insulin resistance and 
atherosclerosis, a considerable number of pathogenic 
pathways might be shared in the development of both 
conditions. In the past decades traditional approaches 
have been confined to identify changes in the expres-
sion levels of individual genes between two different 
conditions, however the integration and comprehension 
of large amounts of data remained a challenge [8–10]. 
Recently several methods and bioinformatic tools have 
been developed to perform pathways analyses out of 
gene expression data enabling to manage, integrate and 
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interpret them with a more holistic view and a biological 
meaning [11, 12]. Gene set enrichment analysis (GSEA) 
provides the possibility to compare data with different 
gene set databases of interest and reports group of genes 
associated with the same biological function or common 
pathways [12, 13]. Hence such analyses allow a more 
general picture on dysregulation compared to analyses 
focusing on individual genes.
Despite a number of investigations focusing on altera-
tions leading to the development of either insulin 
resistance or atherosclerosis, there is no record in the 
literature systematically looking for dysregulated path-
ways common to insulin resistance and atherosclerosis in 
the same individual. Due to the concurring risk of type 
2 diabetes and cardiovascular disease, the elucidation of 
dysregulated pathways in adipose tissue and atheroscle-
rotic plaques should be based on an animal model that 
mirrors human disease by simultaneously developing 
adipose tissue inflammation/insulin resistance and ath-
erosclerosis. Therefore, the aim of this study was the 
identification and analysis of common dysregulated path-
ways in obesity-induced adipose tissue inflammation and 
atherosclerotic plaque formation to elucidate interrela-
tions in the concurrent development of type 2 diabetes 
and cardiovascular disease. Increasing our understand-
ing on simultaneous dysregulation may indicate common 
molecular mechanisms that underlie type 2 diabetes and 
cardiovascular disease to facilitate novel preventive and 
therapeutic strategies in patients with metabolic syn-
drome. In this study we performed a pathway analysis 
using GSEA software with data from an own microarray 
experiment carried out with gonadal white adipose tissue 
(AT) and aortae (AO) samples from a combined insulin 
resistance/atherosclerosis mouse model established in 
our lab [14]. With this inbred mouse model, we identified 
common pathways in the onset of adipose tissue inflam-
mation/insulin resistance and atherosclerosis taking 
advantage of the simultaneous development of both of 
them in individual mice while avoiding genetic variation. 
In conclusion, this study provides a highly valuable set of 
information which may be used by multiple researchers 
to generate hypotheses on the common development of 
insulin resistance and atherosclerosis.
Methods
Animals and diets
A combined insulin resistance/atherosclerosis mouse 
model established in our laboratory was used as 
described [14]. At 9  weeks of age, male LDL-receptor 
knockout mice (Ldlr−/−) were placed for 20 weeks either 
on normal chow (NC; V1126-000, Ssnif, Soest, Germany) 
or diabetogenic diet (DDC; D09071704, Research Diets 
Inc.) (Additional file 1: Table S1). Animals were sacrificed 
and AT and AO were collected and immediately snap fro-
zen in liquid nitrogen. All mice were housed in a specific 
pathogen-free facility with a 12 h light/dark cycle. Mice 
had free access to food and water. The protocol fully com-
plied with the guidelines on accommodation and care of 
animals formulated by the European Convention for the 
Protection of Vertebrate Animals Used for Experimental 
and Other Scientific Purposes and was approved by the 
local ethics committee for animal studies and the Aus-
trian Federal Ministry for Science and Research.
Atherosclerosis quantification
En-face staining was used to determine atherosclerotic 
plaque formation as described [15]. Briefly, after sacri-
ficing the mice the thorax was opened and the aorta was 
removed and cleaned removing all fat and connective 
tissue. Subsequently, the aorta was excised 2 mm above 
aortic root and below iliac bifurcation, opened longitudi-
nally, pinned to silicone plates with acupuncture needles 
(asia-med, Suhl, Germany) and fixed overnight in 4  % 
paraformaldehyde, 5  % sucrose, 20  μM EDTA (pH 7.4). 
Atherosclerotic plaques were stained with Sudan IV for 
15  min and destained with 75  % ethanol. Pictures were 
taken with a Sony Z-1000 camera and atherosclerotic 
lesion area was assessed by a person blinded to the sam-
ples by using ImageJ software.
Microarray analysis
The frozen tissue samples were homogenized in TRIzol® 
reagent (Invitrogen/Life Technologies, Carlsbad, CA, 
USA) and processed based on manufacturer’s instruc-
tions for the RNA isolation. Total RNA (1 μg) was used 
for GeneChip analysis, for AT preparation six individual 
samples were used, whereas in the case of AO each of the 
three individual samples were pooled in three groups due 
to a limited quantity of material. Terminal labeled cDNA, 
hybridization to genome-wide Mouse Gene 2.0 ST 
Gene Chips and scanning of the arrays were carried out 
according to the manufacture’s indications (Affymetrix). 
Robust Multiarray Average (RMA) signal extraction, 
normalization and filtering were performed as described 
(http://www.bioconductor.org) [16, 17]. The data dis-
cussed in this publication have been deposited in NCBI’s 
Gene Expression Omnibus (TM. Stulnig et al. 2016) and 




For the GSEA analysis, output primary raw data from 
the AT or AO microarray experiments was set up as the 
expression data set in accordance with GSEA indica-
tions and uploaded to the software collectively with the 
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phenotype labels, chip annotations and either Biocarta, 
KEGG, Reactome or Hallmark gene sets downloaded 
from the Molecular Signatures Database (MSigDB) from 
the GSEA website. Subsequently the program was run 
with 1000 permutations and gene set as a permutation 
type, obtaining all dysregulated pathways, their respec-
tive normalized enrichment score (NES) and the enrich-
ment plot for each microarray experiment. Statistical 
significances were set at a nominal p < 0.05 and false dis-
covery rate q < 25 %. According to the GSEA directions, 
the pathways upregulated by NC were taken as pathways 
downregulated by DDC.
Afterwards, the leading edge analysis function was 
executed to determine all those genes that significantly 
contribute to the dysregulation of the pathway of interest, 
also called leading genes. GSEA software was also used 
for perform the leading genes heat maps, where higher 
expression values are represented with red and lower 
expression values with dark blue. All Venn diagrams were 
made with the free access Venn Diagram Plotter from the 
Pacific Northwest National Laboratory.
Statistical analyses
Data are given as mean ±  SEM. Dietary treatment dif-
ferences were estimated by unpaired two-tailed Student 
t test.
Results
Diabetogenic diet induces obesity and atherosclerosis 
in Ldlr−/− mice
Male Ldlr−/− mice were fed DDC or NC following the 
combined cardiometabolic mouse model previously 
established and characterized in detail in our lab [14]. 
The key parameters of this model were reevaluated for 
the mice in this study. We observed a significantly higher 
body weight at all time points (Fig. 1a) as well an elevated 
final AT weight (Fig.  1 b) in Ldlr−/− mice fed DDC for 
16 weeks compared to those on NC animals. Atheroscle-
rotic plaque formation as analyzed by en-face staining 
revealed markedly enhanced atherosclerotic lesions in 
Ldlr−/− mice fed with DDC (Fig.  1c, d). Together these 
results point to the simultaneous development of con-
siderable obesity and atherosclerosis in Ldlr−/− mice fed 
with DDC used in this study, reflecting published find-
ings in this mouse model.
GSEA revealed common dysregulated pathways in AT 
and AO from obese mice
In this study, the output primary raw data from the AT 
or AO microarrays were uploaded into the GSEA with 
the aim to determine significantly dysregulated pathways 
in either tissue by the effect of the supplied diets (DDC 
or NC) and possible overlaps in terms of dysregulated 
pathways between both tissues. The analyses were com-
pared with Biocarta, KEGG, Reactome or Hallmark as 
gene sets, obtaining upregulated pathways by DDC or 
NC for either AT or AO (Fig. 2). To identify common dys-
regulated pathways between AT and AO, we proceeded 
to match the upregulated or downregulated pathways for 
both tissues in each of the four analyses finding a consid-
erable overlap in all the gene sets. The highest proportion 
of overlapping pathways was obtained for the Hallmark 
gene set (Fig.  3). Hence, the Hallmark gene set analy-
sis was chosen for more comprehensive examinations, 
which allowed us to elucidate common pathways related 
to obesity induced AT inflammation and atherosclerosis.
Hallmark gene set involves many well characterized 
biological processes combining numerous pathways. The 
dysregulated pathways from the GSEA with the Hall-
mark gene set are shown in Table 1 and were ranked by 
AT microarray NES, the main statistic to evaluate gene 
set enrichment. Several well-known as well as novel path-
ways potentially involved in type 2 diabetes and athero-
sclerosis were dysregulated in AT and AO from obese 
and atherosclerotic animals, respectively, compared with 
healthy counterparts. Upregulation of inflammatory 
genes with positive NES occurred in both AT and AO in 
obesity and atherosclerosis. With respect to a pathway 
downregulated in obese adipose tissue (negative NES), 
we selected the oxidative phosphorylation pathway due 
to experimental and clinical evidence linking mitochon-
drial alterations to type 2 diabetes and atherosclerosis.
Single gene analysis of inflammatory response 
and oxidative phosphorylation pathways
To investigate changes at the single gene level involved 
in the inflammatory response and oxidative phospho-
rylation pathways, we first proceeded with a leading 
edge analysis, which allowed us to identify those genes 
that are significantly affecting the dysregulation of each 
pathway, called leading genes. The leading genes are rep-
resented in the heatmaps (Figs. 4, 5) and in the pathway 
enrichment plots (Additional files 2, 3). The enrichment 
score that gives an idea about the overall regulation of 
the pathway is represented by the score at the peak of the 
enrichment plot. We carried out a leading edge analysis 
for the inflammatory response pathway in obese adipose 
tissue (Fig. 4a) and in atherosclerotic aortae (Fig. 4b) as 
well as for the oxidative phosphorylation pathways also 
in obese adipose tissue (Fig.  5a) and in atherosclerotic 
aortae (Fig.  5b). For the obese adipose tissue, a definite 
leading genes regulation profile was observed in all the 
samples in both analyzed pathways, denoted by the clear 
color patterns in the heatmaps (Figs. 4a, 5a). In contrast 
to the AT results, the leading gene regulation profile 
either in the inflammatory response or in the oxidative 
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phosphorylation pathways was not quite homogenous in 
all the AO samples (Figs. 4b, 5b). Nevertheless, the oxida-
tive phosphorylation pathway was clearly downregulated 
in obese/atherosclerotic animals as shown in Table  1, 
heatmaps and enrichment plots.
We next tested for a possible overlap between the 
leading genes of each pathway in AT and AO. The per-
centage of matched leading genes from AT and AO in 
the inflammatory response pathway was 36 % (Fig. 6a), 
while it was even 54  % in oxidative phosphorylation 
(Fig. 6b). Additionally, the lists of common leading genes 
between both tissues for the inflammatory response 
pathway (Table 2) or oxidative phosphorylation pathway 
(Table  3) were obtained together with the correspond-
ing rank metric score per gene which represents their 
importance in the dysregulation of the pathway with the 
uppermost listed genes being the most influential in the 
pathway in AT (Upregulated, Table  2; Downregulated, 
Table  3). For the inflammatory response pathway Il7r, 
C3ar1, Tlr1, Rgs1 and Semad4d were the highest ranked 
genes. Among the most highly ranked in the oxidative 
phosphorylation pathway were Maob, Bckdha, Aldh6a1, 
Echs1 and Cox8a. Non-overlapping genes regulated 
solely in AT or AO for inflammatory response and oxi-
dative phosphorylation pathways are listed in the Addi-
tional file 1: Tables S2, S3, respectively. In addition, the 
common leading genes of the other pathways dysregu-
lated in both analyzed tissues that have not been further 
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Fig. 1 Diabetogenic diet induces obesity and atherosclerosis in Ldlr−/− mice. Ldlr−/− mice were placed on either diabetogenic diet (DDC) or 
normal chow (NC) for 16 weeks: a mean body weight during dietary treatment (n = 12); b mean gonadal white adipose tissue (AT) weight after 
16 weeks on dietary treatment (n = 12); c representative images of en‑face Sudan IV stained aortae after 16 weeks of indicated treatments; d ath‑
erosclerotic lesion quantification after 16 weeks of dietary treatment (n = 3)
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Discussion
Type 2 diabetes and cardiovascular disease are com-
mon risks inherent with presence of metabolic syndrome 
and are triggered by insulin resistance and atherosclero-
sis, respectively. Several immunological and metabolic 
changes in serum levels from factors such as TNF-α [18], 
IL-6 [19], plasminogen activator inhibitor (PAI-1) [20], 
C-reactive protein (CRP) and fibrinogen [21], have been 
reported to be altered during insulin resistance and adi-
pose tissue inflammation, both consequences of obesity, 
as well as atherosclerotic plaque formation during dyslip-
idemias [22, 23]. Even though diverse studies have been 
carried out to determine common variations at gene or 
protein levels between different metabolic tissues during 
obesity, the common pathways involved in the simulta-
neous development of adipose tissue inflammation and 
atherosclerosis remained elusive. Identification of com-
mon dysregulated pathways, however, could be a key in 
the development of both conditions and provide a chance 
for novel strategies to simultaneously prevent type 2 dia-
betes and cardiovascular disease in subjects at risk, i.e. 
those with metabolic syndrome [24, 25]. Pathway-based 
analysis is a powerful tool that allows to detect changes 
at a higher biological level than individual genes or mol-
ecules, complementing single gene level approaches with 
biological interactions, and thus contributing to a better 
understanding of the complexity of diseases [13]. Taking 
this together with the high reliability of the microarray 
technology nowadays [26–28], the pathways analyses 
based on microarray data can be considered as remark-
ably robust studies at the meta level. There are several 
publications showing single pathways to be involved in 
type 2 diabetes [29, 30] or atherosclerosis [31–33], such 
as focal adhesion [34], angiotensin II-NFκB [35], electron 
carrier activity, PPAR signaling and protein secretion 
[36]. However, in this study, we combined adipose tis-
sue inflammation and atherosclerosis, in order to iden-
tify common dysregulated pathways in a systematical and 
unbiased manner, merging own and published data and 
applying different bioinformatic approaches.
Initially, we took advantage of a recently established 
combined insulin resistance/atherosclerosis inbred 
mouse model and analyzed microarray raw data from 
AT and AO with the GSEA software. Using four differ-
ent gene sets, Biocarta, KEGG, Reactome and Hallmark 
(Fig.  2) we obtained considerably overlaps of dysregu-
lated pathways in each of the four analyses. We choose 
Hallmark results to conduct a deeper look. However, 
to consider data from Biocarta, KEGG and Reactome 
Fig. 2 Study design and pathways GSEA results overview. The data 
from gonadal white adipose tissue (AT) and atherosclerotic aorta (AO) 
microarrays were analyzed by GSEA software with Biocarta, KEGG, 
Reactome or Hallmark as gene sets. Upregulated or downregulated 
pathways in AT or AO by the effect of the diabetogenic diet (DDC) are 
shown
Fig. 3 Venn diagrams plots for the dysregulated pathways according 
to GSEA. Upregulated or downregulated pathways for obese gonadal 
white adipose tissue (AT) and atherosclerotic aorta (AO) are shown in 
the Venn diagrams for each of the four analyses: a biocarta, b KEGG, c 
reactome, d Hallmark. Common pathways and percentage of overlap 
are included in the central region of each diagram
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analyses remains an interesting aim for further studies 
(Fig. 3).
Interestingly, the Hallmark analysis results included 
novel as well as already described common dysregulated 
pathways related with insulin resistance and ath-
erosclerosis such as inflammatory response, IL6 JAK 
STAT3 signaling, TNFA signaling via NFKB, inter-
feron gamma response, fatty acid metabolism, oxidative 
Table 1 Dysregulated pathways from obese adipose tissue and atherosclerotic aortae after Hallmark-GSEA analysis
Commonly dysregulated pathways in AT and AO are shown in italics
Dysregulated pathways are sorted by descending NES in AT
a Dysregulated pathways
b Obese white adipose tissue
c Atherosclerosic aortae
d Normalized enrichment score
e Nominal p value
f False discovery rate
g Inflammation related pathways
h Metabolism related pathways
DPa NESd NOM p-Vale FDRf IRPg MRPh Name
ATb AOc AT AO AT AO AT AO
x x 2.43 1.35 <0.001 0.047 0.000 0.098 E2F targets
x x 2.39 1.74 <0.001 <0.001 0.000 0.004 G2 M checkpoint
x x 2.15 2.27 <0.001 <0.001 0.000 0.000 x Allograft rejection
x x 2.12 2.33 <0.001 <0.001 0.000 0.000 x Inflammatory response
x x 2.08 1.99 <0.001 <0.001 0.000 0.001 x IL6 JAK STAT3 signaling
x x 1.99 1.90 <0.001 <0.001 0.000 0.001 Epithelial mesenchymal transition
x x 1.97 1.97 <0.001 <0.001 0.000 x TNFA signaling via NFKB
x x 1.88 1.75 <0.001 <0.001 0.000 Mitotic spindle
x x 1.86 2.10 <0.001 <0.001 0.000 0.000 Complement
x x 1.86 2.10 <0.001 <0.001 0.000 x Kras signaling up
x x 1.81 1.41 0.002 0.045 0.001 Protein secretion
x x 1.72 1.89 <0.001 <0.001 0.004 0.001 Apoptosis
x x 1.63 –1.34 0.001 0.026 0.008 0.091 x MTORC1 signaling
x x 1.60 2.35 0.001 <0.001 0.011 0.000 x Interferon gamma response
x x 1.58 1.61 0.021 0.021 0.013 0.011 x Angiogenesis
x x 1.50 1.48 0.006 0.012 0.027 0.035 Coagulation
x 1.48 0.012 0.030 Unfolded protein response
x 1.43 0.015 0.047 MYC targets V1
x 1.41 0.024 0.051 x Androgen response
x 1.36 0.027 0.073 x IL2 STAT5 signaling
x x 1.34 1.68 0.024 <0.001 0.084 P53 pathway
x x −1.45 −1.72 0.016 <0.001 0.036 0.004 x Peroxisome
x −1.56 <0.001 0.000 Myogenesis
x x −1.65 −2.14 <0.001 <0.001 0.000 0.000 x Bile acid metabolism
x x −1.86 –1.46 <0.001 0.003 0.000 0.038 Xenobiotic metabolism
x x –2.17 –2.40 <0.001 <0.001 0.000 0.000 x Fatty acid metabolism
x x –2.44 −2.15 <0.001 <0.001 0.000 0.000 x Oxidative phosphorylation
x x −3.06 −2.38 <0.001 <0.001 0.000 0.000 x Adipogenesis
x 2.08 <0.001 0.000 x Interferon alpha response
x 1.72 <0.001 0.005 Heme metabolism
x 1.63 0.001 0.010 Apical junction
x 1.50 0.007 0.031 x Hypoxia
x –1.77 <0.001 0.002 Spermatogenesis
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phosphorylation and adipogenesis (Table  1). This list of 
pathways could be of a great tool for researchers who 
are interested in the common mechanisms behind adi-
pose tissue inflammation and atherosclerosis, since 
common genes enclosed in the pathways could be new 
Fig. 4 Leading genes heat map expression for the inflammatory 
response pathway in AT and AO. Leading genes of the inflammatory 
response pathway in: a gonadal white adipose tissue (AT) and b aorta 
(AO) are represented in the heatmaps. Upregulated genes are repre‑
sented in red and downregulated genes are represented in blue
Fig. 5 Leading genes heat map expression for the oxidative phos‑
phorylation pathway in AT and AO. Leading genes of the oxidative 
phosphorylation pathway in: a gonadal white adipose tissue (AT) and 
b aorta (AO) are represented in the heatmaps. Upregulated genes are 
represented in red and downregulated genes are represented in blue
▸
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targets to investigate mechanism as well as possible 
future treatments.
After evaluation of the common pathways altered in 
both metabolic processes, we selected the inflammatory 
and oxidative phosphorylation pathways as representa-
tives of up- and down-regulated pathways, respectively, 
due to the importance of the involved genes in the patho-
genesis of type 2 diabetes and atherosclerosis [37–41]. 
We could show a clear expression pattern for all genes 
that contribute to the dysregulation of the pathway in 
each tissue (Figs. 4, 5). The upregulation of the inflamma-
tory response pathway in inflamed adipose tissue as well 
as in atherosclerotic aorta in the animal model used in 
Fig. 6 Venn diagrams plot of leading genes involved in the enrich‑
ment score of inflammatory response and phosphorylation pathways. 
Percentage of the overlap between the leading genes from the 
inflammatory response (a) and oxidative phosphorylation (b) path‑
ways in obese white adipose tissue (AT) and in atherosclerotic aortae 
(AO)
Table 2 Common genes from  obese adipose tissue and  atherosclerotic aortae involved in  the inflammatory response 
pathway
Dysregulated genes are sorted by descending rank metric score in AT
a Obese gonadal white adipose tissue
b Atherosclerotic aortae
Rank metric score Gene symbol Gene name
ATa AOb
4.554 2.000 Il7r Interleukin 7 receptor
3.713 2.000 C3ar1 Complement component 3a receptor 1
3.652 0.928 Emr1 Adhesion G protein‑coupled receptor E1
3.489 0.579 Tlr1 Toll‑like receptor 1
3.298 1.000 Rgs1 Regulator of G‑protein signalling 1
3.285 0.576 Semad4d Semaphorin 4D
3.205 0.940 Cybb Cytochrome b‑245 heavy chain
3.175 0.445 Kcnj2 Inward rectifier potassium channel 2
3.111 0.779 C5ar1 C5a anaphylatoxin chemotactic receptor 1
3.037 1.000 Cd48 CD48 antigen
2.961 1.000 Pik3r5 Phosphoinositide‑3‑kinase, regulatory subunit 5, p101
2.626 0.992 Ptafr Platelet‑activating factor receptor
2.422 0.894 Ptpre Protein tyrosine phosphatase, receptor type, E
2.364 0.716 P2rx4 Purinergic receptor P2X, ligand‑gated ion channel, 4
2.346 2.000 Timp1 Tissue inhibitor of metalloproteinase 1
2.197 2.000 Il10ra Interleukin 10 receptor, alpha
1.692 0.519 Plaur Plasminogen activator, urokinase receptor
1.594 0.496 Clec5a C‑type lectin domain family 5, member a
1.535 0.361 Gna15 Guanine nucleotide binding protein, alpha 15
1.452 0.922 Ccl2 Chemokine (C–C motif ) ligand 2
1.303 0.273 Ifnar1 Interferon (alpha and beta) receptor 1
1.129 0.957 Ccl7 Chemokine (C–C motif ) ligand 7
1.090 1.000 Csf3r Colony stimulating factor 3 receptor (granulocyte)
0.921 0.460 Il1r1 Interleukin 1 receptor, type I
0.905 0.697 Ccl5 Chemokine (C–C motif ) ligand 5
0.882 0.782 Icam1 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
0.806 0.277 Slc11a2 Solute carrier family 11, member 2
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Table 3 Common genes from obese adipose tissue and atherosclerotic aortae involved in the oxidative phosphorylation 
pathway
Rank metric score Gene symbol Gene name
ATa AOb
−2.2950 −0.4060 Maob Monoamine oxidase B
−2.0570 −0.3260 Bckdha Branched chain keto acid dehydrogenase E1, alpha polypeptide
−2.0250 −0.8910 Aldh6a1 Aldehyde dehydrogenase 6 family, member A1
−2.0020 −0.2060 Echs1 Enoyl CoA hydratase, short chain, 1, mitochondrial
−1.7080 −0.3710 Cox8a Cytochrome c oxidase subunit 8a
−1.4980 −0.7180 Phyh Phytanoyl–CoA hydroxylase
−1.4240 −0.1680 Cox4i1 Cytochrome c oxidase subunit IV isoform 1
−1.3880 −0.3800 Aco2 Aconitase 2, mitochondrial
−1.3400 −0.2640 Acat1 Acetyl‑Coenzyme A acetyltransferase 1
−1.3350 −0.2220 Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8
−1.3200 −0.1620 Ndufv1 NADH dehydrogenase (ubiquinone) flavoprotein 1
−1.3060 −0.3470 Atp5d ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit
−1.2750 −0.2330 Ndufs7 NADH dehydrogenase (ubiquinone) Fe–S protein 7
−1.2670 −0.4190 Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4
−1.2370 −0.2430 Gpx4 Glutathione peroxidase 4
−1.2260 −0.4390 Pdha1 Pyruvate dehydrogenase E1 alpha 1
−1.2060 −0.4440 Sdhc Succinate dehydrogenase complex, subunit C, integral membrane protein
−1.2030 −0.3650 Cs Citrate synthase
−1.1660 −0.3270 Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1
−1.1510 −0.2410 Ndufa8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8
−1.1450 −0.1990 Cox6b1 Cytochrome c oxidase subunit Vib polypeptide 1
−1.1290 −0.3140 Mrps15 Mitochondrial ribosomal protein S15
−1.1150 −0.2280 Idh3 g Isocitrate dehydrogenase 3 (NAD+) gamma
−1.0870 −0.1990 Acadvl Acyl‑Coenzyme A dehydrogenase, very long chain
−1.0820 −0.1850 Ndufa9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9
−1.0620 −0.3370 Cox6a1 Cytochrome c oxidase subunit VIa polypeptide 1
−1.0570 −0.2870 Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1
−1.0470 −0.1760 Mfn2 Mitofusin 2
−1.0230 −0.5940 Pdhb Pyruvate dehydrogenase (lipoamide) beta
−1.0140 −0.3930 Idh3b Isocitrate dehydrogenase 3 (NAD+) beta
−0.9750 −0.5050 Atp5g3 ATP synthase, H + transporting, mitochondrial F0 complex, subunit C3 (subunit 9)
−0.9440 −0.1990 Uqcrfs1 Ubiquinol‑cytochrome c reductase, Rieske iron‑sulfur polypeptide 1
−0.9060 −0.2240 Mrpl34 Mitochondrial ribosomal protein L34
−0.8870 −0.2150 Uqcrh Ubiquinol‑cytochrome c reductase hinge protein
−0.8840 −0.3650 Grpel1 GrpE−like 1, mitochondrial
−0.8440 −0.2340 Uqcrc2 Ubiquinol‑cytochrome c reductase core protein 2
−0.8300 −0.1600 Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6
−0.8010 −0.5270 Ldhb Lactate dehydrogenase B
−0.7460 −0.2100 Phb2 Prohibitin 2
−0.7320 −0.2170 Mrpl11 Mitochondrial ribosomal protein L11
−0.7270 −0.4530 Cox6c Cytochrome c oxidase subunit VIc
−0.7160 −0.6190 Cox5b Cytochrome c oxidase subunit Vb
−0.7090 −0.1590 Suclg1 Succinate‑CoA ligase, GDP‑forming, alpha subunit
−0.7080 −0.2300 Cox7b Cytochrome c oxidase subunit VIIb
−0.7030 −0.1930 Atp5j ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F
−0.6970 −0.3770 Cox5a Cytochrome c oxidase subunit Va
−0.6920 −0.2190 Dlst Dihydrolipoamide S‑succinyltransferase
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this study complements the recent findings showing after 
a long term high fat diet (16 weeks) that the homeosta-
sis of the immune system is altered from a physiological 
immune response to a pathological state [42]. Moreo-
ver, the down-regulation of the oxidative phosphoryla-
tion pathway in AT supports the observations indicating 
decreased expression of the genes implicated in the mito-
chondria electron chain in visceral adipose tissue in type 
2 diabetes [39]. However, our study shows the down-reg-
ulation of the oxidative phosphorylation pathway also in 
the atherosclerotic aorta. Additionally we also identified 
a considerable number of common genes between both 
analyzed tissues that significantly contribute to the dys-
regulation of the inflammatory response or the oxida-
tive phosphorylation pathways and could be potentially 
involved in the pathogenesis of both type 2 diabetes and 
cardiovascular disease (Fig. 6; Tables 2, 3).
A large amount of studies have been performed to 
identify potential treatment strategies for multifactorial 
diseases which are caused by a collective dysregulation 
of many genes. Recently, identification of dysregulated 
pathways was proposed as possible biomarkers for such 
disorders [43, 44]. This study conferred a strong evidence 
of similarities on the pathogenesis between insulin resist-
ance and atherosclerosis, which could support diagnos-
tic processes and drug design in a more effective manner 
facilitating a more personalized medicine in patients with 
metabolic syndrome.
Conclusion
In conclusion, we describe analogies at the pathway as 
well as individual gene level between obese adipose tissue 
and atherosclerotic aortae potentially to be considered as 
a basis to achieve novel therapeutic approaches for the 
simultaneous prevention of type 2 diabetes and athero-
sclerotic cardiovascular disease.
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Dysregulated genes are sorted by descending rank metric score in AT
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Table 3 continued
Rank metric score Gene symbol Gene name
ATa AOb
−0.6890 −0.2280 Atp5 h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit D
−0.6880 −0.3350 Mdh1 Malate dehydrogenase 1, NAD (soluble)
−0.6860 −0.3760 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3
−0.6670 −0.2560 Mrpl35 Mitochondrial ribosomal protein L35
−0.6340 −0.2650 Prdx3 Peroxiredoxin 3
−0.6270 −0.2690 Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5
−0.6050 −0.2480 Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5
−0.5830 −0.5650 Sdhd Succinate dehydrogenase complex, subunit D, integral membrane protein
−0.5760 −0.1720 Ndufs8 NADH dehydrogenase (ubiquinone) Fe–S protein 8
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